BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

BTIG analyst Julian Harrison has reiterated a Buy rating on Cullinan Therapeutics (NASDAQ: CGEM) and has maintained a price target of $40 for the stock. This endorsement suggests confidence in the company's future performance.